Palopegteriparatide in Chronic Hypoparathyroidism

This is a multicenter, prospective cohort study conducted across 9 tertiary and university hospitals in the rural area of Athens, which investigates the clinical and biochemical effects of palopegteriparatide (TransCon PTH) in adult patients with chronic hypoparathyroidism (≥12 months). Eligible participants included those transitioning from conventional therapy (activated vitamin D analogs and oral calcium) and those previously treated with rhPTH(1-84). The primary objective was to assess the time to independence from activated vitamin D and calcium supplementation. Secondary objectives included changes in biochemical parameters, incidence of clinically significant hypo- and hypercalcemia during the titration period , and reduction in daily pill burden. Patients received individualized doses of palopegteriparatide with follow-up visits at regular intervals, and safety was monitored throughout the study according to standard clinical practice.

NCT Number	NCT07299838
Lead Sponsor	National and Kapodistrian University of Athens Collaborators: G.Gennimatas General Hospital, Alexandra Hospital, Athens, Greece, Theagenio Cancer Hospital, 251 Hellenic Air Force & VA General Hospital, Laikο General Hospital, Athens, KAT General Hospital, Hellenic Red Cross Hospital, Hippocration General Hospital, Evaggelismos Hospital, Greece
Conditions	Hypoparathyroidism
Enrollment	90 participants
Start Date	2024-06-01
Primary Completion	2025-09-30 (estimated)
Study Completion	2025-10-23 (estimated)
Updated on ClinicalTrials.gov	2026-01-26